UK markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
116.09-1.91 (-1.62%)
At close: 04:00PM EDT
116.09 0.00 (0.00%)
After hours: 07:54PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500

IndustryDiagnostics & Research
Full-time employees10,590

Key executives

NameTitlePayExercisedYear born
Mr. Jacob Thaysen Ph.D.CEO & Director796.63kN/A1975
Ms. Carissa L. RollinsChief Information Officer693.52kN/A1970
Mr. Charles E. Dadswell Esq.Senior VP & General Counsel1.03MN/A1959
Stephanie CamposPresidentN/AN/AN/A
Mr. Ankur DhingraChief Financial OfficerN/AN/A1976
Mr. Kevin Carl PegelsChief of Global OperationsN/AN/A1968
Mr. Scott EricksenVP & Chief Accounting OfficerN/AN/A1973
Dr. Steven Barnard Ph.D.Chief Technology OfficerN/AN/AN/A
Ms. Sallilyn SchwartzVice President of Investor RelationsN/AN/AN/A
Mr. Jakob WedelChief Strategy & Corporate Development Officer and CEO Chief of StaffN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Corporate governance

Illumina, Inc.’s ISS governance QualityScore as of 1 July 2024 is 2. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.